107 related articles for article (PubMed ID: 7353778)
21. Measurement of prostate-specific antigen in detection of benign or malignant breast disease in women.
Romppanen J; Keskikuru R; Kataja V; Eskelinen M; Kosma VM; Savolainen K; Uusitupa M; Mononen I
Br J Cancer; 1999 Mar; 79(9-10):1583-7. PubMed ID: 10188910
[TBL] [Abstract][Full Text] [Related]
22. [Determination of plasma prolactin in patients with breast dysplasia].
Vázquez Albaladejo C; Ferrer S; Merle S; Sanchis V; Camps Roig J; Giménez Climent J
Rev Esp Oncol; 1983; 30(3):323-36. PubMed ID: 6571376
[TBL] [Abstract][Full Text] [Related]
23. [Prolactin. Radioimmunoassay in female breast cancers and benign mastopathies].
Gorins A; Netter A
Nouv Presse Med; 1974 Jan; 3(2):73-5. PubMed ID: 4815434
[No Abstract] [Full Text] [Related]
24. Oral contraceptive use and fibrocystic breast disease with special reference to its histopathology.
Pastides H; Kelsey JL; LiVolsi VA; Holford TR; Fischer DB; Goldenberg IS
J Natl Cancer Inst; 1983 Jul; 71(1):5-9. PubMed ID: 6575209
[TBL] [Abstract][Full Text] [Related]
25. Serum hormones in human breast cancer subjects.
Krishnamoorthy G; Govindarajulu P; Ramalingam V
Neoplasma; 1989; 36(2):221-31. PubMed ID: 2497392
[TBL] [Abstract][Full Text] [Related]
26. Serum oestradiol-17 beta and prolactin concentrations during the luteal phase in women with benign breast disease.
Walsh PV; McDicken IW; Bulbrook RD; Moore JW; Taylor WH; George WD
Eur J Cancer Clin Oncol; 1984 Nov; 20(11):1345-51. PubMed ID: 6542005
[TBL] [Abstract][Full Text] [Related]
27. [Hormonal abnormalities in women with breast cysts].
Wypych K; Kuźlik R; Wypych P
Ginekol Pol; 2002 Nov; 73(11):1117-25. PubMed ID: 12722409
[TBL] [Abstract][Full Text] [Related]
28. Association of cyst type with risk factors for breast cancer and relapse rate in women with gross cystic disease of the breast.
Naldoni C; Costantini M; Dogliotti L; Bruzzi P; Bucchi L; Buzzi G; Torta M; Angeli A
Cancer Res; 1992 Apr; 52(7):1791-5. PubMed ID: 1551110
[TBL] [Abstract][Full Text] [Related]
29. Serum prolactin and growth hormone determined by radioimmunoassay and a two-site immunoradiometric assay: comparison with the Nb2 cell bioassay.
Rose DP; Berke B; Cohen LA
Horm Metab Res; 1988 Jan; 20(1):49-53. PubMed ID: 3371857
[TBL] [Abstract][Full Text] [Related]
30. Prostate-specific antigen in the serum of women with benign breast disease.
Radowicki S; Kunicki M; Bandurska-Stankiewicz E
Eur J Obstet Gynecol Reprod Biol; 2008 Jun; 138(2):212-6. PubMed ID: 17850950
[TBL] [Abstract][Full Text] [Related]
31. Influence of hormonal status of patients with cystic disease on the composition of cyst fluid and breast cancer risk.
Budai B; Számel I; Sulyok Z; Németh M; Bak M; Kralovánszky J; Ottó S; Besznyák I; Purohit A; Parish DC; Reed MJ
Anticancer Res; 2000; 20(5C):3879-86. PubMed ID: 11268470
[TBL] [Abstract][Full Text] [Related]
32. Ultradian (12-hr) significant component in serum prolactin of healthy women and patients with fibrocystic mastopathy.
D'Allesandro B; Esposito V; Lo Iudice G; Cagnoni M; Tarquini B
Prog Clin Biol Res; 1987; 227B():281-4. PubMed ID: 3628338
[TBL] [Abstract][Full Text] [Related]
33. Danazol treatment of chronic cystic mastopathy: a clinical and hormonal evaluation.
Dhont M; Delbeke L; van Eyck J; Voorhoof L
Postgrad Med J; 1979; 55 Suppl 5():66-70. PubMed ID: 395523
[TBL] [Abstract][Full Text] [Related]
34. Anovulation and increased androgenic activity as breast cancer risk in women with fibrocystic disease of the breast.
Gratterola R
Cancer Res; 1978 Sep; 38(9):3051-4. PubMed ID: 679211
[TBL] [Abstract][Full Text] [Related]
35. [Fibro-cystic mastosis and cancer (206 cases of mastosis in possible relation with 12 cases of cancer)].
Chardot C; Varroy A; Parache RM
Bull Cancer; 1970; 57(2):251-68. PubMed ID: 5505161
[TBL] [Abstract][Full Text] [Related]
36. Endocrine aspects of benign breast disease.
Parlati E; Liberale I; Travaglini A; Morelli P; Menini E; Dell'Acqua S
Cancer Detect Prev; 1992; 16(1):25-6. PubMed ID: 1312904
[TBL] [Abstract][Full Text] [Related]
37. [Bromocriptine in fibro-cystic mastopathy].
Marzetti L; Framarino ML; Dei Malatesta ML; Aragona C; De Angelis R
Riv Ital Ginecol; 1980; 59(4-5):357-64. PubMed ID: 7313397
[No Abstract] [Full Text] [Related]
38. Treatment of benign breast disease with bromocriptine.
Mussa A; Dogliotti L
J Endocrinol Invest; 1979; 2(1):87-91. PubMed ID: 489922
[TBL] [Abstract][Full Text] [Related]
39. Hormones and the pathophysiology of fibrocystic mastopathy: elevated luteinizing hormone levels.
Golinger RC; Krebs J; Fisher ER; Danowski TS
Surgery; 1978 Aug; 84(2):212-5. PubMed ID: 684613
[TBL] [Abstract][Full Text] [Related]
40. Permanent alterations induced in plasma prolactin and estrogen receptor concentration in benign and malignant tissue of women who started oral contraceptive use at an early age.
Olsson H; Lindahl B; Ranstam J; Borg A; Fernö M; Norgren A
Anticancer Res; 1987; 7(4B):853-6. PubMed ID: 3674773
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
